Focused On-demand Library for Tetratricopeptide repeat protein 19, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q6DKK2

UPID:

TTC19_HUMAN

Alternative names:

Alternative UPACC:

Q6DKK2; A8MZ52; B3KP62; B4DN65; Q2M248; Q7L3U8; Q9H6G3; Q9NXB2

Background:

Tetratricopeptide repeat protein 19, mitochondrial (TPR19), plays a crucial role in maintaining the structural and functional integrity of mitochondrial respiratory complex III. It facilitates the physiological turnover of the Rieske protein UQCRFS1, essential for cellular energy production. TPR19 is also involved in the clearance of UQCRFS1 N-terminal fragments, enhancing complex III's catalytic activity.

Therapeutic significance:

TPR19's involvement in Mitochondrial complex III deficiency, nuclear type 2, a disorder affecting multiple body systems, underscores its therapeutic potential. Targeting TPR19 pathways could lead to novel treatments for mitochondrial disorders, emphasizing the importance of understanding its biological mechanisms.